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adipose tissue culture model, in part 
through adiponectin
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Adipose tissue (AT) macrophages (ATM) play a key role in obesity-associated pathol-
ogies, and their phenotype can be influenced by the local tissue microenvironment. 
Interestingly, long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) and the LC n-3 
PUFA-upregulated adipokine, adiponectin (Ad), may mitigate excessive ATM inflamma-
tory M1-polarization responses. However, to what extent LC n-3 PUFA and Ad work in 
concert to affect macrophage phenotype has not been examined. Thus, we used an 
established ex vivo AT organ culture model using visceral AT from mice fed a control 
(CON; 10% w/w safflower oil) n-6 PUFA-rich diet or an isocaloric fish oil (FO; 3% w/w 
menhaden oil + 7% w/w safflower oil)-derived LC n-3 PUFA-rich diet to generate AT 
conditioned media (ACM). We then evaluated if CON or FO ACM affected macrophage 
polarization markers in a model designed to mimic acute [18 h ACM plus lipopolysac-
charide (LPS) for the last 6 h] or chronic (macrophages treated with LPS-challenged 
CON or FO ACM for 24  h) inflammation  ±  Ad-neutralizing antibody and the LPS-
neutralizing agent, polymyxin B. In the acute inflammation model, macrophages treated 
with FO ACM had decreased lipid uptake and mRNA expression of M1 markers (Nos2, 
Nfκb, Il6, Il18, Ccl2, and Ccl5) compared with CON ACM (p ≤ 0.05); however, these 
effects were largely attenuated when Ad was neutralized (p > 0.05). Furthermore, in the 
chronic inflammation model, macrophages treated with FO ACM had decreased mRNA 
expression of M1 markers (Nos2, Tnfα, Ccl2, and Il1β) and IL-6 and CCL2 secretion 
(p ≤ 0.05); however, some of these effects were lost when Ad was neutralized, and were 
Abbreviations: ACM, adipose tissue conditioned media; Ad, adiponectin; AT, adipose tissue; ATM, adipose tissue macrophage; 
CD, cluster of differentiation; CCL, chemokine (c–c motif) ligand; CON, control; DHA, docosahexaenoic acid; EPA, eicosapen-
taenoic acid; FO, fish oil; IL, interleukin; iNOS, inducible nitric oxide synthase; LC n-3 PUFA, long-chain n-3 polyunsaturated 
fatty acids; LF, low-fat; LPS, lipopolysaccharide; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; NLRP, 
NOD-like receptor family, Pyrin domain containing; PBS, phosphate buffered saline; Px, polymyxin B; ROS, reactive oxygen 
species; TLR, toll-like receptor; TNFα, tumor necrosis factor alpha.
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inTrODUcTiOn
In obesity, adipose tissue macrophages (ATM) play a key role in 
adipose tissue (AT) inflammation and subsequent development 
of obesity-associated pathologies, such as local and systemic 
insulin resistance (1, 2). More specifically, circulating monocytes 
accumulate in obese AT, particularly in visceral depots, wherein 
they differentiate into ATM to help with tissue remodeling and 
lipid homeostasis (3–5). Importantly, paracrine interactions, 
or cross-talk, between adipocytes and ATM play a key role in 
determining macrophage polarization status (i.e. M1 or M2) and 
the resultant AT secretory profile. Many ATM exhibit an inflam-
matory M1 phenotype, characterized by increased lipid content, 
NLRP3 inflammasome activation, expression of the integrin 
(CD11b) and high levels of anti-microbicidal iNOS (murine 
only), antigen presentation via MHCII, and secretion of inflam-
matory cytokines, such as TNFα and IL-6 (6–9). Mechanistically, 
TNFα and IL-6 feedback onto adipocytes through paracrine 
signaling to sustain secretion of adipocyte-derived inflammatory 
mediators (e.g., CCL2, IL-6) and release of fatty acids through 
lipolysis (10). Finally, some ATM exhibit a less inflammatory M2 
phenotype, characterized by surface expression of scavenging 
receptors, such as CD206, antigen presentation, and secretion of 
the anti-inflammatory cytokine, IL-10 (6).
Obesity is also characterized by increased circulating levels 
of gut bacteria-derived lipopolysaccharide (LPS), a condition 
termed as metabolic endotoxemia (11), which leads to LPS 
accumulation in AT (4). While some macrophages can exhibit 
endotoxin tolerance or hypo-responsiveness when re-stimulated 
with LPS (12), it is unclear if this occurs in macrophages within 
obese AT. Interestingly, both the full-length (13–15) and globular 
(16–18) isoforms of the anti-inflammatory adipokine, adiponec-
tin (Ad), have been shown to promote a response similar to 
endotoxin tolerance and macrophage polarization toward the 
M2 phenotype, or enhance M2 polarization in  vitro (19) and 
in  vivo (20). Therefore, Ad could potentially serve to re-direct 
the cyclic inflammatory cross-talk between adipocytes and M1 
macrophages in obesity.
Given the impact of the ATM phenotype on subsequent 
inflammatory processes and AT dysfunction, strategies to alter 
ATM polarization status may be useful in mitigating obesity-
related inflammation. Of interest, dietary long-chain polyun-
saturated fatty acids (LC n-3 PUFA), such as eicosapentaenoic 
acid (20:5 n-3, EPA) and docosahexaenoic acid (22:6 n-3, DHA), 
are well-known anti-inflammatory agents (21, 22) and can serve 
to mitigate excessive inflammatory adipocyte–macrophage par-
acrine interactions in vitro (23, 24). Although it has been shown 
that LC n-3 PUFA lessen inflammatory adipokine secretion (25) 
and M1 macrophage polarization in obese rodent AT (26–29), 
the mechanisms by which this occurs are unclear. Furthermore, 
while LC n-3 PUFA upregulate secretion of Ad in murine (30) 
and human adipocytes (31), it is unclear if Ad partly mediates the 
anti-inflammatory effects of LC n-3 PUFA.
Thus, to assess the potential role of Ad in LC n-3 PUFA-
mediated anti-inflammatory effects on ATMs, we used an 
established ex vivo AT organ culture method (32) composed of 
visceral AT from mice fed a control (CON) safflower oil-derived 
n-6 PUFA-rich diet or a fish oil (FO)-derived LC n-3 PUFA-rich 
diet to generate AT conditioned media (ACM). We then evaluated 
if CON or FO ACM affected macrophage polarization markers 
in an acute inflammation model in the absence or presence of 
Ad-neutralizing antibody. Second, we used a low-grade chronic 
inflammation model whereby visceral AT organ cultures from 
CON and FO diet fed mice were challenged with LPS ex vivo for 
24 h prior to incubation with macrophages to mimic the chronic 
inflammation of metabolic endotoxemia (11, 33). Additionally, 
we utilized both an Ad-neutralizing antibody and the LPS-
neutralizing agent, polymyxin B, to assess if Ad or LPS driven 
mechanisms affect LC n-3 PUFA-mediated anti-inflammatory 
effects in macrophages treated with ACM in the chronic inflam-
mation model.
MaTerials anD MeThODs
animals and Diets
All experimental procedures were approved by the University of 
Guelph Animal Care Committee. Mice were housed as described 
(34). Eight-week-old male C57BL/6 mice were fed ad libitum an 
AIN-93G modified diet containing either 10% w/w safflower oil 
(CON) or an isocaloric LC n-3 PUFA-enriched diet containing 
3% w/w menhaden oil + 7% w/w safflower oil (FO) for 4 weeks 
(n = 5 mice/diet), [Research Diets Inc., USA; composition previ-
ously reported (34)]. To prevent diet oxidation the common food 
anti-oxidant, t-Butylhydroquinone, was added to the diets, diets 
were stored at −20°C prior to use, and mouse food was changed 
every 2 days to limit oxidation. The FO diet contained approxi-
mately 1.7% kcal from LC n-3 PUFA, which is in line with the 
human dietary recommended intake of 0.5–2% kcal for total n-3 
PUFA (35).
Tissue collection and aT Organ culture
Mice were terminated by CO2 asphyxiation followed by cervical 
dislocation. Epididymal fat pads were isolated and immediately 
placed into 50  mL sterile conical tubes containing 1× PBS 
(Sigma, USA). Fat pads were blotted dry, approximately cut 
into two equal portions, and then weighed. Tissue was divided 
further exacerbated when both Ad and LPS were neutralized. Taken together, this work 
shows that LC n-3 PUFA and Ad work in concert to suppress certain M1 macrophage 
responses. Thus, future strategies to modulate the ATM phenotype should consider the 
role of both LC n-3 PUFA and Ad in mitigating obese AT inflammation.
Keywords: obesity, adipose tissue, M1 macrophage, n-3 polyunsaturated fatty acids, adiponectin, 
lipopolysaccharide
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into two per depot so that one sample could be challenged with 
low-dose LPS (10 ng/mL) from E. coli serotype 055:B5 (Sigma, 
USA, cell culture tested, one lot used) intended to mimic the 
5–6 endotoxin units reported in metabolic endotoxemia (11, 
33). Immediately after weighing, fat pads were moved to 15 mL 
sterile conical tubes containing 3 mL of DMEM high glucose 
(without sodium pyruvate, HyClone, USA) supplemented with 
0.5% v/v fetal bovine serum (sterile filtered, Canadian origin, 
Sigma, USA); a source of anti-oxidants in vitro (36), and 1% v/v 
penicillin–streptomycin (HyClone, USA). Each tissue sample 
was immediately minced using sterile scissors into ≤0.5  cm 
pieces to avoid tissue hypoxia. Under sterile conditions, media 
was then topped up so that the ratio of tissue to media was at 
the optimal ratio of 500  mg/15  mL media as reported in the 
optimized method elsewhere (32). To the tissues challenged 
with LPS, an LPS working solution was added to the culture 
media such that the final concentration was 10 ng/mL. AT sam-
ples were placed into 100 mm sterile culture dishes (Sarstedt, 
USA) and then cultures were placed in a humidified incubator 
for 24 h at 37°C with 5% CO2. Twenty-four hours were chosen 
since secreted cytokines were elevated between 12 and 24  h 
(Figure  1). After the incubation period, the minced AT was 
removed using 70  μm sterile cell strainers (BD Biosciences, 
USA), and the ACM was aliquoted and stored at −80°C until 
further analysis.
Preparation of Macrophage acM 
Treatments
The ACM was thawed once and then sterile filtered (0.22 μm, 
Sarstedt, USA) prior to use. Before incubation with macrophages, 
5 μg/mL of Ad-neutralizing antibody (AF1119, anti-mAcrp30, 
R&D Systems, USA) or isotype control anti-goat IgG (5 μg/mL, 
R&D Systems, USA) was added to ACM. The samples were then 
incubated at 4°C as previously reported (37). This antibody was 
chosen since it has been reported to suppress Ad-mediated sign-
aling in adipocyte-conditioned media (37, 38), and we confirmed 
the dose of antibody used suppressed Ad-mediated signaling 
in pilot experiments with adipocyte-conditioned media (data 
not shown). In the acute inflammation model (Figures  2–4), 
macrophages were pre-treated with ACM from CON or FO fed 
mice (no LPS) for 18 h, followed by the addition of LPS (10 ng/
mL) to the ACM for the final 6 h (total 24 h). This time course 
was chosen since both globular (18) and full-length Ad (15) have 
previously been shown to promote a response similar to endo-
toxin tolerance using a comparable time course. In the chronic 
inflammation model (Figures 5–7), visceral AT organ cultures 
from CON and FO diet fed mice were challenged with LPS ex vivo 
for 24 h prior to incubation with macrophages for an additional 
24 h. Ad-neutralizing antibody was added to ACM as described 
above. Additionally, the LPS-neutralizing agent, polymyxin B 
(36 μM, 0.22 μm sterile filtered, cell-culture tested, Sigma, USA), 
was added to some ACM treatments with gentle vortexing every 
10  min for a total of 30  min prior to administering ACM to 
macrophages at 37°C. For all experiments, macrophages treated 
with media containing 5 μg/mL IgG plus 10 ng/mL LPS served 
as the control.
culture of raW 264.7 Macrophages
RAW 264.7 murine macrophages (ATCC, USA) were grown 
and passaged according to the manufacturer’s instructions. 
Macrophages were maintained in DMEM high glucose (without 
sodium pyruvate, HyClone, USA), plus 10% v/v fetal bovine 
serum (low-endotoxin, Canadian origin, Sigma, USA), and 1% 
v/v penicillin streptomycin (HyClone, USA). Four hours prior 
to experiments, macrophages were split using the manufacturer’s 
protocol, counted using trypan exclusion, spun down at 335 × g at 
ambient temperature for 5 min, and then re-suspended in DMEM 
high glucose plus 0.5% v/v FBS and 1% v/v penicillin strepto-
mycin. Next, the cell density was adjusted to 1.0 × 106 cells/mL 
and macrophages were seeded into 96-well (for oil red O pro-
cedure) or 24-well plates (for RNA/protein analysis) (Corning, 
USA). Without disturbing the adherent macrophages, media was 
replaced with the aforementioned control, CON or FO ACM 
treatments.
gene expression
After 24 h, cells were washed with 1× PBS, lysed using a RNA/
Protein Isolation Kit (Norgen Biotek, Canada), and processed 
according to the manufacturer’s instructions. cDNA was made 
from 1 μg of extracted RNA using a high capacity cDNA reverse 
transcription kit as per the manufacturer’s instructions (Applied 
Biosystems, USA). Real-time PCR analysis was performed using a 
7900HT Fast Real-Time PCR system (Applied Biosystems, USA) 
using the default protocol described elsewhere (23). Primers were 
designed using the Universal Probe Library Assay Design Center 
(Roche Applied Sciences, Germany, Table  1) and validated 
primer efficiencies were between 90 and 105%. All results were 
normalized to 18S mRNA expression, and the relative differences 
in gene expression between treatment groups and the IgG control 
(no LPS) were determined using the ΔΔCt method.
secreted adipokine analyses
Supernatant was collected after 12 and 24  h from ACM, and 
after 24 h following ACM culture with macrophages for analysis 
of secreted cytokine concentrations. CCL2 (MCP-1), CCL5 
(RANTES), CCL7 (MCP-3), IL-4, IL-6, IL-10, IL-18, IL-1β, and 
TNFα were multiplexed using the ProcartaPlex Mouse Basic kit 
(eBioscience, USA) using undiluted supernatant and analyzed 
using the Bio-Plex 200 System (Bio-Rad, USA). To calculate 
the secretion of adipokines solely from macrophages after 24 h 
treatment with ACM, the concentration of cytokine measured 
in ACM prior to culture with macrophages was subtracted from 
the concentration of cytokine measured after the incubation. 
Importantly, cell protein and secreted levels of IL-1β and IL-18 
were below the minimum detection threshold for all treatments. 
Additionally, secreted full-length Ad was diluted 100-fold and 
measured by ELISA (Quantikine Mouse Ad/Acrp 30 ELISA, R&D 
Systems, USA) according to the manufacturer’s instructions.
Macrophage Fatty acid composition
Following 24 h, macrophages were scraped in 1× PBS and then 
centrifuged at 335 × g at ambient temperature for 10 min. The 
PBS was aspirated and the pellet was frozen at −80°C until further 
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processing. Total lipids were extracted from cell lysates of mac-
rophages and fatty acid methyl esters were prepared for analysis 
by gas liquid chromatography as described previously (39, 40). 
Fatty acids were identified by comparing the retention times of 
samples with those of a known standard (GLC463; Nu-Chek 
Prep, USA). Fatty acid composition values are expressed as a 
percentage of total fatty acids. Within each ACM treatment, the 
lipid profile between macrophages treated with Ad-neutralizing 
antibody to those treated with IgG did not differ; therefore, only 
ACM treatments (IgG) are shown (Figures 2 and 5).
Macrophage Oil red O Procedure
Following the 24  h ACM treatment, neutral lipid deposition 
was assessed in macrophages with minor modification from the 
FigUre 1 | Time course secretion of adipokines from cOn and FO acM at 12 and 24 h. The secretion of M1-associated adipokines IL-6, TNFα, CCL2, 
CCL5, CCL7 (a) and adiponectin (B) from CON and FO ACM at 12 and 24 h time points ± LPS challenge. AT organ cultures from epididymal AT of CON or FO fed 
mice were treated with or without low-dose LPS (10 ng/mL) for 24 h. Data show the means ± SEM for CON and FO (n = 5/diet/condition). Bars not sharing a letter 
are significantly different (p ≤ 0.05).
FigUre 2 | neutral lipid and total lipid profile in macrophages in the acute inflammation model. Macrophages were treated with CON or FO ACM (no LPS) 
for 18 h, followed by the addition of low-dose LPS (10 ng/mL) for the last 6 h (24 h total). 5 μg/mL of anti-Ad or IgG were added to ACM treatments prior to culture 
with macrophages. Macrophages treated with media and 5 μg/mL IgG plus LPS served as the control. Data show the means ± SEM (n = 5/diet/condition). Bars not 
sharing a letter are significantly different (p ≤ 0.05).
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original procedure (41). Briefly, an oil red O working solution was 
made 6 h in advance by mixing 6 parts oil red O saturate (0.5 g 
in 100 mL isopropyl alcohol) in 4 parts ddH2O, and then filtered 
twice immediately before use. Next, media was aspirated and 
cells were then rinsed with 1× PBS. Cultures were fixed with 4% 
paraformaldehyde solution followed by light shaking at ambient 
temperature for 10 min. Cultures were then sequentially rinsed 
with 1× PBS and 70% ethanol before staining with oil red O 
working solution for 30 min (at ambient temp with light shaking). 
Following this, cultures were then rinsed again with 1× PBS, then 
70% ethanol solution. The solutions were then aspirated and the 
plate was inverted to dry in a laminar flow hood for 30 min. Next, 
200 μL of isopropyl alcohol was added to each well. The plate was 
sealed, shook lightly for 3 min, and then read immediately with 
a spectrophotometer at 520 nm. Wells without cells that received 
the aforementioned staining procedure served as the plate blank. 
Data are reported as the fold change in absorbance (per treat-
ment) relative to the average absorbance for cells cultured in 
media without LPS or other additives (n = 4).
statistical analysis
All data are expressed as mean ± SEM. The predetermined upper 
limit of probability for statistical significance was p ≤ 0.05 and 
analyses were conducted using SigmaPlot version 12.5 (USA). 
Data that were not normally distributed were transformed 
prior to statistical analysis, and normal distribution and equal 
variance were confirmed by Shapiro–Wilk test and Levene’s 
test, respectively. Data were analyzed using a two-way ANOVA 
followed, if justified, by testing using Fisher’s Least Squared 
Difference post  hoc test. Mouse parameters comparing CON 
and FO diets (Table 2) and macrophage lipid content between 
CON and FO ACM (Figures  2 and 5) were analyzed using 
unpaired t-tests.
resUlTs
Mouse Parameters
Mouse initial and terminal body weights, dietary food intake, and 
epididymal fat pad weights did not differ between mice fed CON 
or FO diets (p > 0.05, Table 2). Previous studies using these diets 
showed that LC n-3 PUFA are significantly enriched in liver and 
red blood cells (42).
acM secretory Profile after 24 h  
With or Without lPs
In CON ACM, IL-6, TNFα, CCL2, CCL5, and CCL7 secretion 
increased in the presence of LPS at both 12 and 24 h (Figure 1). 
Similarly, in FO ACM, IL-6, CCL2, and CCL5 secretion increased 
when LPS was added at both 12 and 24 h; however, TNFα secre-
tion only increased at 24  h (p ≤  0.05, Figure  1). Moreover, in 
FO ACM, secretion of CCL7 did not change over time or with 
LPS (p > 0.05, Figure 1). Interestingly, in FO ACM without LPS, 
the secretion of IL-6, TNFα, CCL2, and CCL5 were decreased 
relative to CON ACM at both 12 and 24 h; however, CCL7 was 
only decreased at 24  h (p ≤  0.05, Figure  1). Similarly, relative 
to CON ACM with LPS, in FO ACM with LPS the secretion of 
IL-6 was decreased at both 12 and 24 h, although the secretion 
FigUre 3 | mrna expression of M1 markers Nos2, Nfκb, Ccl2, Tnfα, Il6, Ccl5, nlrP3 inflammasome genes (Casp1, Il18, and Il1β) (a), and secretion 
of M1-associated cytokines il-6 and ccl2 (B) from macrophages treated with acM ± anti-ad in the acute inflammation model. Macrophages were 
treated with CON or FO ACM (no LPS) for 18 h, followed by the addition of low-dose LPS (10 ng/mL) for the last 6 h (24 h total). 5 μg/mL of anti-Ad or IgG were 
added to ACM treatments prior to culture with macrophages. Macrophages treated with media with 5 μg/mL IgG plus LPS served as the control. Data show the 
means ± SEM (n = 5/diet/condition). Bars not sharing a letter are significantly different (p ≤ 0.05).
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FigUre 4 | mrna expression of M2-associated markers Il10, Cd206, and Cd86 (a) and secretion of il-10 (B) from macrophages treated with 
acM ± anti-ad in the acute inflammation model. Macrophages were treated with CON or FO ACM (no LPS) for 18 h, followed by the addition of low-dose LPS 
(10 ng/mL) for the last 6 h (24 h total). 5 μg/mL of anti-Ad or IgG were added to ACM treatments prior to culture with macrophages. Macrophages treated with 
media and 5 μg/mL IgG + LPS served as the control. Data show the means ± SEM (n = 5/diet/condition). Bars not sharing a letter are significantly different 
(p ≤ 0.05).
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of other adipokines was only decreased at one time point (CCL2, 
CCL5, and CCL7 at 24 h; TNFα at 12 h), (p ≤ 0.05, Figure 1). 
Furthermore, the secretion of full-length Ad in ACM did not vary 
with diet or LPS (p > 0.05, Figure 1). Finally, IL-1β, IL-18, IL-4, 
and IL-10 concentrations were below the range of detection in all 
ACM treatments.
lipid Profile in Macrophages  
Treated With acM in the acute 
inflammation Model
To examine if the Ad within ACM from CON or FO fed mice 
could promote a response similar to endotoxin tolerance, mac-
rophages were pre-treated with ACM or media for 18  h with 
Ad-neutralizing antibody (anti-Ad) or control IgG, then LPS was 
added for 6 h for a total of 24 h. First, we measured total lipid 
uptake using oil red O staining to measure the relative abundance 
of neutral lipids, and then quantified the percent of total lipids 
(n-3 and n-6 PUFA, MUFA, and SFA) within the macrophages 
treated for 24 h with CON or FO ACM (Figure 2). Here, without 
LPS, macrophages treated with CON ACM had increased neutral 
lipid relative to control (p ≤  0.05); however, no such increase 
occurred in macrophages treated with FO ACM (p  >  0.05, 
Figure 2). Second, adding LPS resulted in an increase in neutral 
lipid in control macrophages (p  ≤  0.05, Figure  2). However, 
levels of neutral lipid did not change when LPS was added in 
macrophages treated with CON or FO ACM (p > 0.05, Figure 2). 
Interestingly, when LPS was added to ACM with anti-Ad, levels 
of neutral lipid increased in macrophages treated with FO ACM 
(p ≤ 0.05), but not CON ACM (p > 0.05, Figure 2). Finally, the 
percent of n-3 PUFA (0.24 ± 0.04%), n-6 PUFA (0.33 ± 0.03%), 
MUFA (4.30 ±  0.24%) and SFA (95.2 ±  0.22%) did not differ 
in macrophages treated with CON or FO ACM in this model 
(p > 0.05, Figure 2).
FigUre 5 | neutral lipid uptake and total lipid profile in macrophages treated with acM ± anti-ad and Px in the chronic inflammation model. 
Macrophages were treated with ACM from LPS-challenged CON or FO AT organ cultures for 24 h. 5 μg/mL of anti-Ad (or IgG) ± polymyxin B (36 μM; Px) were 
added to ACM treatments prior to culture with macrophages. Macrophages treated with media and 5 μg/mL IgG plus 10 ng/mL LPS ± Px served as the control. 
Data show the means ± SEM (n = 5/diet/condition). Bars not sharing a letter are significantly different (p ≤ 0.05). An asterisk indicates that the CON group is 
significantly different than the respective FO group (p ≤ 0.05).
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mrna expression of M1 Markers and 
associated secreted cytokines in 
Macrophages Treated With acM in the 
acute inflammation Model
First, treating macrophages with low-dose LPS for 6  h (con-
trol) induced the expression of M1 markers and NLRP3 
inflammasome-related genes shown in Figure 3 relative to mac-
rophages treated with just IgG (data not shown, p ≤ 0.05). Second, 
treating macrophages with either CON or FO ACM induced a 
response similar to endotoxin tolerance at the mRNA level as 
evidenced by decreased expression of M1 markers, Nfκb, Ccl2, 
Tnfα, Il6, and Ccl5, as well as NLRP3 inflammasome-associated 
genes Nlrp3, Il18, and Il1β (Figure 3A, p ≤  0.05). By contrast, 
FigUre 6 | mrna expression of M1 markers Itgam and Nos2 (a), associated cytokines Tnfα, Il6, and Ccl2 (B), nlrP3 inflammasome genes Nlrp3, 
Il18, and Il1β (c), and key Mhcii-related antigen presentation genes Cd74, Cd80, and Cd86 (D) from macrophages treated with acM ± anti-ad and 
Px in the chronic inflammation model. Macrophages were treated with ACM from LPS-challenged (10 ng/mL) CON or FO AT organ cultures for 24 h. 5 μg/mL of 
anti-Ad (or IgG) ± polymyxin B (36 μM; Px) were added to ACM treatments prior to culture with macrophages. Macrophages treated with media and 5 μg/mL IgG 
and 10 ng/mL LPS ± Px served as the control. Data show the means ± SEM (n = 5/diet/condition). Bars not sharing a letter are significantly different (p ≤ 0.05).
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FigUre 7 | secretion of M1-associated cytokines (il-6, ccl2, and TnFα) and anti-inflammatory cytokine, il-10 from macrophages treated with 
acM ± anti-ad and Px in the chronic inflammation model. Macrophages were treated with ACM from LPS-challenged (10 ng/mL) CON or FO AT organ 
cultures for 24 h. 5 μg/mL of anti-Ad (or IgG) ± polymyxin B (36 μM; Px) were added to ACM treatments prior to culture with macrophages. Macrophages treated 
with media and 5 μg/mL IgG and 10 ng/mL LPS ± Px served as the control. Data show the means ± SEM (n = 5/diet/condition). Bars not sharing a letter are 
significantly different (p ≤ 0.05).
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macrophages treated with CON ACM had increased mRNA 
expression of Nos2 relative to control (Figure  3A, p ≤  0.05), 
whereas mRNA expression of Casp1 in macrophages treated 
with CON or FO ACM did not differ from control (Figure 3A, 
p  >  0.05). Second, when anti-Ad was added, within each 
respective ACM group, the mRNA expression of M1 markers, 
Nos2 (CON ACM only), Tnfα, Il6, and Ccl5, as well as NLRP3 
inflammasome-related genes, Casp1, Nlrp3, and Il18 (Figure 3A), 
decreased (p ≤ 0.05). By contrast, relative to each respective ACM 
treatment group, mRNA expression of Il1β increased with anti-
Ad (p ≤ 0.05, Figure 3A). Third, mRNA expression of M1 genes, 
Nos2 (FO ACM only), Nfκb, and Ccl2 decreased in macrophages 
treated with ACM regardless of adding anti-Ad (Figure  3A). 
Additionally, relative to CON ACM, macrophages treated with 
FO ACM had decreased mRNA expression of Nos2, Nfκb, Ccl2, 
Il6, Ccl2, and Il18 (p ≤ 0.05), although this effect was lost for Nos2, 
Nfκb, Ccl2, and Il18 with anti-Ad (p > 0.05, Figure 3A). Fourth, 
secretion of IL-6 and CCL2 increased in both CON and FO ACM-
treated macrophages relative to control; however, with anti-Ad, 
secretion of IL-6 and CCL2 (CON ACM only) returned to control 
levels (p >  0.05, Figure 3B). Interestingly, in FO ACM-treated 
macrophages, secretion of CCL2 was elevated above all treatment 
groups, although this was partly subdued with anti-Ad (p ≤ 0.05, 
Figure 3B).
mrna expression of M2 Markers 
and secreted il-10 in Macrophages 
Treated With acM in the acute 
inflammation Model
Treating macrophages with low-dose LPS for 6  h (control) 
induced mRNA expression of M2 markers, Il10 and Cd206, and 
the antigen presentation co-stimulatory molecule, Cd86, relative 
to macrophages treated with just IgG (data not shown, p ≤ 0.05). 
Macrophages treated with CON ACM had decreased mRNA 
expression of Il10 relative to control, while macrophages treated 
with both CON and FO ACM had decreased Cd86 relative to 
control (p ≤ 0.05, Figure 4A). However, when anti-Ad was added 
to CON and FO ACM, mRNA expression of both Il10 and Cd206 
were decreased (p ≤ 0.05, Figure 4A). Third, mRNA expression 
of Cd86 in macrophages treated with FO ACM was decreased 
relative to CON ACM, though this effect was lost with anti-Ad 
TaBle 2 | Mouse physiological parametersa.
Parameter cOn FO
Initial body weight (g) 21.0 ± 0.63 21.8 ± 0.52
Terminal body weight (g) 25.0 ± 2.2 27.5 ± 1.2
Food intake (g/day) 2.24 ± 0.04 2.22 ± 0.03
Epididymal fat pad weight (g) 1.36 ± 0.27 1.45 ± 0.15
aValues are means ± SEM (n = 5/dietary group).
TaBle 1 | Primer sequences.
gene name Forward primer (5′–3′) reverse primer (3′–5′)
18S ACGGAAGGGCACCACCAGGA CACCACCACCCACGGAATCG
Casp1 CCCACTGCTGATAGGGTGAC GCATAGGTACATAAGAATGAACTGGA
Ccl2 GCCTGCTGTTCACAGTTGC CAGGTGAGTGGGGCGTTA
Ccl5 TCCAATCTTGCAGTCGTGTTTG TCTGGGTTGGCACACACTTG
Cd206 CCACAGCATTGAGGAGTTTG ACAGCTCATCATTTGGCTCA
Cd74 CGCCCTAGAGAGCCAGAAA TTGCTGGTACAGGAAGTAAGCA
Cd80 TCGTCTTTCACAAGTGTCTTCAG TTGCCAGTAGATTCGGTCTTC
Cd86 GAAGCCGAATCAGCCTAGC CAGCGTTACTATCCCGCTCT
Il6 AACGATGATGCACTTGCAGA GAGCATTGGAAATTGGGGTA
Il10 GGTTGCCAAGCCTTATCGGA ACCTGCTCCACTGCCTTGCT
Il1β AGTTGACGGACCCCAAAAG AGCTGGATGCTCTCATCAGG
Il18 CAAACCTTCCAAATCACTTCCT TCCTTGAAGTTGACGCAAGA
Itgam AGCCCCACACTAGCATCAA TCCATGTCCACAGAGCAAAG
Nfκb GAGACCGGCAACTCAAGAC CTCAGGTCCATCTCCTTGGGT
Nlrp3 CCCTTGGAGACACAGGACTC GAGGCTGCAGTTGTCTAATTCC
Nos2 TCCTGTTGTTTCTATTTCCTTTGTT CATCAACCAGTATTATGGCTCCT
Tnfα CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC
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(p ≤  0.05, Figure  4A). Finally, IL-10 secretion was increased 
(p ≤  0.05) in macrophages treated with CON ACM relative to 
control regardless of adding anti-Ad (Figure  4B). By contrast, 
IL-10 secretion decreased in macrophages treated with FO ACM 
relative to control and CON ACM (p ≤ 0.05), and this occurred 
regardless of adding anti-Ad (Figure 4B).
lipid Profile in Macrophages Treated With 
acM in the chronic inflammation Model
To examine if the Ad within ACM from CON or FO fed mice 
could affect macrophage phenotype in a chronic inflammation 
model, macrophages were treated with ACM collected from LPS-
challenged visceral AT organ cultures or control media for 24 h 
with anti-Ad or control IgG. Additionally, within ACM samples, 
LPS was neutralized by polymyxin B (Px) to test if Ad worked 
synergistically with LPS. First, in macrophages treated with CON 
or FO ACM, we measured the relative abundance of neutral lipids 
after 24 h using oil red O staining and then quantified the percent 
of total n-3 and n-6 PUFA, MUFA and SFA relative to total fatty 
acid content (only showing those above 0.2% trace amounts of 
total lipid) (Figure  5). Interestingly, macrophages treated with 
CON ACM had similar neutral lipid relative to control; however, 
neutral lipid increased when Px, anti-Ad, or anti-Ad plus Px 
were added to CON ACM (p ≤  0.05, Figure  5). By contrast, 
macrophages treated with FO ACM only had elevated levels 
of neutral lipid compared to control when anti-Ad or anti-Ad 
plus Px were added to FO ACM (p ≤  0.05, Figure 5). Second, 
compared to macrophages treated with CON ACM, macrophages 
treated with FO ACM had increased total n-3 PUFA, n-6 PUFA 
and MUFA, while total SFA decreased (p ≤ 0.05, Figure 5). More 
specifically, macrophages treated with FO ACM had increased 
n-3 PUFA, including docosapentaenoic acid (DPA, 22:5 n-3) and 
docosahexaenoic acid (DHA, 22:6 n-3); increased n-6 PUFA, 
including linoleic acid (LA, 18:2 n-6) and arachidonic acid (AA, 
20:4 n-6); and increased MUFA, including palmitoleic (16:1 c9), 
oleic (18:1 c9), and vaccenic (18:1 c11) acid (p ≤ 0.05, Figure 5). 
With regards to SFAs, macrophages treated with FO ACM also 
had increased myristic acid (14:0), while stearic acid (18:0) was 
decreased (p ≤ 0.05, Figure 5).
mrna expression of M1 Markers in 
Macrophages Treated With acM in the 
chronic inflammation Model
Treating macrophages with low-dose LPS for 24  h (control) 
induced the expression of M1 markers relative to macrophages 
treated with just IgG (data not shown, p ≤ 0.05), and adding Px to 
media with LPS suppressed this expression (p ≤ 0.05, Figure 6A). 
First, Itgam (CD11b) and Nos2 were similarly expressed in control 
macrophages and macrophages treated with CON ACM; how-
ever, mRNA expression of Nos2 decreased in FO ACM-treated 
macrophages (p ≤ 0.05, Figure 6A). Interestingly, with anti-Ad 
added, mRNA expression of Itgam in CON ACM increased above 
control levels (p ≤ 0.05, Figure 6A). Similarly, with anti-Ad in 
FO ACM, expression of Nos2 increased to be similar to the 
control group (p > 0.05, Figure 6A). Second, adding Px to ACM 
decreased mRNA expression of Itgam and Nos2 in each respective 
ACM group; however, when both anti-Ad and Px were added to 
ACM, mRNA expression of Itgam and Nos2 increased compared 
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to each respective ACM group with Px (p ≤  0.05, Figure 6A). 
Intriguingly, in the FO ACM treatment with anti-Ad and Px, 
mRNA expression of Itgam increased above all other treatment 
groups (p ≤ 0.05, Figure 6A). Finally, with regard to differences 
between CON and FO ACM groups, mRNA expression of Nos2 
was decreased in the FO ACM group even with Px or anti-Ad 
(p ≤ 0.05, Figure 6A).
Moreover, macrophages treated with CON ACM had 
decreased mRNA expression of Tnfα relative to control, 
although expression of Il6 was similar to control, and expres-
sion of Ccl2 was greater than control (p ≤ 0.05, Figure 6B). By 
contrast, macrophages treated with FO ACM had decreased 
mRNA expression of Tnfα and Il6 relative to control (p ≤ 0.05), 
and expression of Ccl2 was similar between these two groups 
(p >  0.05, Figure  6B). Second, when anti-Ad was added to 
each respective ACM group, increased mRNA expression of Il6 
and Ccl2 was observed in the FO ACM group only (p ≤ 0.05, 
Figure  6B). Third, adding Px to ACM decreased the mRNA 
expression of Tnfα, Il6, and Ccl2 in each respective ACM group; 
however, when both anti-Ad and Px were added to ACM, 
mRNA expression of these cytokines significantly increased in 
each respective ACM group with Px (with the exception of Tnfα 
expression in the CON ACM group), (p ≤  0.05, Figure  6B). 
Finally, with regards to differences between CON and FO ACM 
groups, mRNA expression of Tnfα and Ccl2 decreased in the 
FO ACM group, even with Px added (p ≤ 0.05); however, this 
relationship was lost with the addition of anti-Ad and anti-Ad 
plus Px to FO ACM (p > 0.05, Figure 6B).
mrna expression of nlrP3 
inflammasome genes in Macrophages 
Treated With acM in the chronic 
inflammation Model
Treating macrophages with low-dose LPS for 24  h (control) 
induced the expression of NLRP3 inflammasome genes relative 
to macrophages treated with just IgG (data not shown, p ≤ 0.05), 
and adding Px to media with LPS (with the exception of Il18) sup-
pressed this expression (p ≤ 0.05, Figure 6C). First, macrophages 
treated with CON ACM had increased mRNA expression of Il18 
relative to the control (p ≤  0.05), whereas expression of Nlrp3 
was less than the control, and expression of Il1β was similar to 
control (p > 0.05, Figure 6C). By contrast, macrophages treated 
with FO ACM had decreased mRNA expression of Nlrp3 and Il1β 
relative to the control (p ≤ 0.05), and expression of Il18 did not 
differ from control (p > 0.05, Figure 6C). In each respective ACM 
group, adding anti-Ad resulted in increased mRNA expression of 
Nlrp3 in both CON and FO ACM groups (p ≤ 0.05, Figure 6C). 
Adding Px in each respective CON or FO ACM group decreased 
mRNA expression of Il18 and Il1β, although Nlrp3 expression 
only decreased in the CON ACM group (p ≤ 0.05, Figure 6C). 
Interestingly, adding anti-Ad and Px to each respective CON or 
FO ACM group compared to ACM with just Px increased mRNA 
expression of Nlrp3, Il18, and Il1β (p ≤ 0.05, Figure 6C). Finally, 
with regards to differences between CON and FO ACM groups, 
mRNA expression of Il18 and Il1β decreased with FO ACM, even 
with anti-Ad was added (p ≤  0.05); however, this relationship 
was lost when anti-Ad plus Px were added to FO ACM (p > 0.05, 
Figure 6C).
mrna expression of Mhcii-related 
antigen Presentation genes in 
Macrophages Treated With acM in the 
chronic inflammation Model
Treating macrophages with low-dose LPS for 24  h (control) 
induced the expression of MHCII-related antigen presenta-
tion genes relative to macrophages treated with just IgG (data 
not shown, p ≤ 0.05), and adding Px to media with LPS (with 
the exception of Cd74) suppressed this expression (p ≤  0.05, 
Figure  6D). First, macrophages treated with CON ACM had 
increased mRNA expression of Cd80 relative to the LPS control 
(p ≤  0.05), whereas expression of Cd74 was similar to control 
(p > 0.05), and expression of Cd86 was less than control (p ≤ 0.05, 
Figure  6D). Moreover, macrophages treated with FO ACM 
had similar levels of Cd74 and Cd80 expression as the control 
(p > 0.05), although expression of Cd86 was less than the control 
(p ≤ 0.05, Figure 6D). Second, when anti-Ad was added, expres-
sion of MHCII-related genes only differed within each respective 
ACM group in one scenario; mRNA expression of Cd80 increased 
in the FO ACM group (p ≤ 0.05, Figure 6D). Third, adding Px to 
each respective ACM group decreased mRNA expression of Cd80 
and Cd86 in both CON and FO ACM (p ≤ 0.05). Interestingly, 
when anti-Ad plus Px were added to each respective ACM group, 
mRNA expression of Cd74, Cd80, and Cd86 increased compared 
to ACM with Px or anti-Ad alone (with the exception of Cd80 
expression in CON ACM with anti-Ad relative to CON ACM 
with anti-Ad and Px) (p ≤ 0.05, Figure 6D). Finally, with regards 
to differences between CON and FO ACM groups, FO ACM 
groups had decreased mRNA expression of Cd74 (between Px 
groups only), Cd80 (between IgG and anti-Ad groups only), and 
Cd86 (between IgG groups only), (p ≤ 0.05, Figure 6D).
secretion of cytokines in Macrophages 
Treated With acM in the chronic 
inflammation Model
First, secretion of all of the aforementioned cytokines increased 
in LPS-treated macrophages after 24  h compared to the IgG 
control (p ≤ 0.05, data not shown). Second, adding Px to the LPS 
control decreased secretion of all of the aforementioned cytokines 
(p ≤ 0.05, Figure 7). Third, relative to control macrophages, those 
treated with CON ACM had increased secretion of IL-6 and CCL2 
(p ≤ 0.05), whereas TNFα was similar (p > 0.05), and secretion 
of IL-10 was less than the control (p ≤ 0.05, Figure 7). Moreover, 
compared to control, in FO ACM, secretion of CCL2 was similar, 
IL-6 was greater, and TNFα and IL-10 were decreased (p ≤ 0.05, 
Figure 7). Fourth, when anti-Ad was added to each respective 
ACM group, the secretion of CCL2 increased in both CON and 
FO ACM, whereas secretion of TNFα increased in the CON ACM 
group only (p ≤  0.05, Figure  7). Fifth, when Px was added to 
each respective ACM group, secretion of TNFα increased in the 
FO ACM group, whereas IL-10 secretion decreased in both the 
CON and FO ACM group (p ≤ 0.05), and secretion of IL-6 and 
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CCL2 did not change (p > 0.05, Figure 7). Sixth, with regards to 
differences between CON and FO ACM groups, FO ACM groups 
had decreased secretion of IL-6 and CCL2 even when Px (with 
the exception of CCL2), anti-Ad, or anti-Ad plus Px were added 
to ACM (p ≤  0.05, Figure  7). Interestingly, when anti-Ad was 
added to ACM there was a decrease in secretion of TNFα and 
IL-10 in the FO ACM group compared to the CON ACM group 
(p ≤ 0.05); however, this effect was lost for TNFα when anti-Ad 
plus Px were added to FO ACM (p > 0.05, Figure 7).
DiscUssiOn
Although it was known that LC n-3 PUFA modulate adipocyte–
macrophage paracrine interactions (23, 24), as well as the AT 
secretory profile in obese mice (25), the effect of LC n-3 PUFA 
on the intact AT secretory profile and how this subsequently 
affects macrophage polarization status was not known. Thus, we 
generated visceral ACM from mice fed a CON (n-6 PUFA-rich) 
or FO (LC n-3 PUFA-rich) diet and then examined its effects 
on macrophage phenotype under different stimulation condi-
tions designed to mimic aspects of the AT microenvironment. 
Specifically, we utilized two models: an acute inflammation model 
to assess if pre-treating macrophages with ACM could promote 
a response similar to endotoxin tolerance in macrophages when 
stimulated with low-dose LPS and a low-grade chronic inflam-
mation model wherein AT organ cultures were challenged 
with LPS to make ACM prior to incubation with macrophages 
to mimic the inflammatory state that occurs in parallel with 
metabolic endotoxemia (11, 33). Here, we report for the first 
time that in the acute inflammation model, macrophages treated 
with FO ACM had decreased lipid uptake (Figure 2), and mRNA 
expression of M1-associated markers (Nos2, Nfκb, Il6, Il18, Ccl2, 
and Ccl5, Figure 3) compared with CON ACM; however, these 
effects were largely attenuated when Ad was neutralized, indicat-
ing that Ad is an important factor in LC n-3 PUFA-mediated 
effects. Furthermore, intact AT from mice fed CON or FO diets 
differed in the secretory response to a low-grade LPS challenge, 
as evidenced by decreased IL-6, CCL2, CCL5, and CCL7 secreted 
from FO ACM (Figure 1). Additionally, in the chronic inflamma-
tion model, compared to CON ACM, macrophages treated with 
FO ACM had decreased mRNA expression of M1-associated 
markers (Nos2, Tnfα, Ccl2, Il1β, Cd80, and Cd86, Figure 6) and 
IL-6 and CCL2 secretion (Figure 7); some of these effects were 
lost when Ad was neutralized, and were further exacerbated 
when both Ad and LPS were neutralized. Taken together, this 
work provides evidence that LC n-3 PUFA and Ad may work 
in concert to suppress specific M1 macrophage responses in a 
microenvironment representative of AT.
Intriguingly, the results suggest that the anti-inflammatory 
effects of LC n-3 PUFA in macrophages may be partly due to 
Ad-mediated signaling, which, to the best of our knowledge, has 
not been previously reported. Although previous studies have 
shown that LC n-3 PUFA increase circulating Ad in rodents 
(43, 44) and humans (45, 46), the current study did not find any 
changes in secreted levels of full-length Ad in ACM due to diet or 
LPS exposure (Figure 1B). This may have occurred because the 
24 h ex vivo period used to generate ACM was not long enough 
to induce changes in the levels of Ad secreted from the AT organ 
cultures; however, this requires further study. Nonetheless, some 
of the anti-inflammatory effects of FO ACM on macrophages in 
both the acute and chronic inflammation models were lost when 
Ad was neutralized. For example, in the acute model, lipid uptake 
increased back to control level in FO ACM-treated macrophages 
when Ad was neutralized in LPS-challenged cells (Figure  2). 
Decreasing lipid uptake may be a mechanism by which LC n-3 
PUFA act to decrease excessive M1 macrophage responses in 
obese AT since lipotoxicity in macrophages is thought to be a 
key driver of M1 macrophage polarization (47). Second, in the 
chronic inflammation model, compared to LPS control, the FO 
ACM-mediated decrease in mRNA expression of M1-associated 
markers (Nos2, Ccl2, Nlrp3, and Cd80, Figure 6) and secretion 
of CCL2 (Figure  7) was lost when Ad was neutralized. Taken 
together, this data suggest that Ad plays a role in LC n-3 PUFA-
mediated anti-inflammatory effects in macrophages, such as 
buffering lipid uptake and mRNA expression of specific markers 
associated with the M1 macrophage phenotype.
Another novel finding in the current study was our data 
showing that Ad may work synergistically with LPS to decrease 
macrophage mRNA expression of M1 markers, particularly in 
FO ACM-treated macrophages in the chronic inflammation 
model. Specifically, M1 markers (Itgam, Il6, Figures  6A,B), 
NLPR3 inflammasome genes (Nlrp3, Il18, Il1β, Figure  6C), 
MHCII-related antigen presentation genes (Cd74, Cd80, Cd86, 
Figure 6D), as well as secretion of IL-6 and TNFα (Figure 7), 
further increased compared to FO ACM with anti-Ad when 
both anti-Ad plus the LPS-neutralizing agent, polymyxin B, were 
added. Along these lines, Park et al. (18, 48) showed that globular 
Ad initially triggers signaling cascades that result in activation 
of NFκB and subsequent TNFα mRNA expression; however, 5 h 
post-induction, this triggered a compensatory anti-inflammatory 
response resulting in IL-10 secretion and subsequent desen-
sitization when re-stimulated with LPS. Thus, Ad may have 
immunoregulating properties in response to an inflammatory 
stimulus, such as LPS, which warrants greater characterization, 
particularly in FO ACM-treated macrophages where some of the 
anti-inflammatory effects of Ad were negated when both Ad and 
LPS were blocked. Indeed, future studies silencing adiponectin 
signaling in primary macrophages would be an effective strategy 
to delineate if adiponectin plays a role in the immunomodulatory 
activity of LC n-3 PUFA in macrophages.
Interestingly, in the acute inflammation model, neutralizing 
Ad in both CON and FO ACM led to a decrease in mRNA expres-
sion of several M1-associated markers (Tnfα, Il6, Ccl5, Figure 3A; 
NLRP3 inflammasome genes Nlrp3, Casp1, Il18, Figure  3A; 
secretion of IL-6 and CCL2, Figure  3B), as well as a decrease 
in expression of M2 markers (Il10 and Cd206, Figure  4). This 
data suggest that Ad promotes mRNA expression of both M1 and 
M2 genes in ACM, which is in line with a previous report show-
ing that M1 macrophages treated with Ad showed more robust 
inflammatory cytokine secretion (e.g., IL-6), and M2 polarized 
macrophages treated with Ad showed more robust IL-10 secretion 
(19). This relationship requires further study in  vivo especially 
given that a recent study in obese mice showed Ad accumulation 
in AT stroma vascular cells, including macrophages (49), further 
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suggesting that Ad could potentially promote more robust M1 
and M2 macrophage polarization in obese AT.
Our findings that FO ACM had marked anti-inflammatory 
effects in macrophages compared to CON ACM in both the 
acute and chronic inflammation models are in agreement with 
other studies showing that LC n-3 PUFA decrease the degree of 
M1 macrophage polarization in the chronically inflamed obese 
AT microenvironment in  vivo (26–29, 50). Notably, compared 
to CON ACM generated from AT organ cultures, FO ACM had 
decreased secreted protein levels of IL-6, CCL2, CCL5, and CCL7 
(Figure 5). Second, compared to CON ACM, FO ACM decreased 
mRNA expression of M1-associated markers in macrophages, 
including Nos2, Nfκb, Il6, Il18, Ccl2, and Ccl5 in the acute model 
(Figure 3A). Third, compared to CON ACM, FO ACM decreased 
mRNA expression of M1 markers (Nos2, Tnfα, Ccl2, Il18, Il1β, 
Cd80, and Cd86, Figure 6) and secretion of IL-6 and CCL2 in 
the chronic inflammation model (Figure 7), and this occurred 
concurrently with changes in the macrophage lipid profile. 
Notably, macrophage LC n-3 PUFA, such as DPA and DHA 
increased, while SFA, such as stearic acid, decreased (Figure 5). 
This data show that LC n-3 PUFA are released from AT within 
ACM and that these fatty acids are subsequently taken up by mac-
rophages. This is not surprising since n-3 PUFA-fed animals and 
humans exhibit increased AT n-3 PUFA storage and mobilization 
[reviewed by Raclot (51)]. Additionally, TLR4 stimulation causes 
DHA and EPA pre-treated macrophages to secrete these PUFA as 
free fatty acids (52), which represents a potential mechanism by 
which LC n-3 PUFA distribute themselves among macrophages 
to mitigate excessive inflammatory responses. Furthermore, 
this change in macrophage lipid profile could partly explain 
some of the anti-inflammatory effects observed after treating 
macrophages with FO ACM. After LC n-3 PUFA are taken up by 
macrophages, the subsequent anti-inflammatory effects may be 
partly due to their incorporation into the phospholipid fraction of 
cellular membranes where they can act to decrease the signaling 
efficiency of protein complexes localized in small, hydrophobic 
membrane microdomains called lipid rafts (53, 54), including the 
TLR4 complex (55); however, this relationship requires further 
study in ACM models.
Treating macrophages with FO ACM also led to changes 
in macrophage mRNA expression of MHCII-related antigen 
presentation genes. Specifically, compared to CON ACM, mac-
rophages treated with FO ACM had decreased mRNA expression 
of co-stimulatory molecules, including Cd86 in the acute inflam-
mation model (Figure 4), and Cd80 and Cd86 (Figure 6D) in the 
chronic inflammation model. This data complements previous 
research showing that LC n-3 PUFA decrease antigen present-
ing cell-mediated co-stimulatory molecule mRNA and surface 
expression (56, 57). Moreover, globular (16, 18) and full-length 
(15, 58–60) Ad promote IL-10 secretion from macrophages. 
IL-10 represses co-stimulatory molecule expression on antigen 
presenting cells (61), suggesting that the Ad-IL-10 axis may affect 
antigen presenting cell functions. In this study, FO ACM-treated 
macrophages did not upregulate IL-10 mRNA expression or 
secretion, suggesting that the FO-mediated decrease in mRNA 
expression of Cd80 and Cd86 occurs independently of IL-10 
in this model. Overall, this data provide preliminary evidence 
that FO may mitigate antigen presentation in macrophages [key 
antigen presenting cells in obese AT (9, 62, 63)] by decreasing 
co-stimulatory molecule expression; however, this relationship 
requires further study.
In summary, we showed for the first time that ACM promotes a 
response similar to endotoxin tolerance in macrophages and that 
macrophages treated with FO ACM had decreased lipid uptake 
and expression of markers associated with an inflammatory M1 
phenotype compared to CON ACM in both the acute and chronic 
inflammation models. Importantly, the anti-inflammatory effect 
of FO ACM on suppressing lipid uptake and M1 marker expres-
sion in macrophages was partly lost when Ad was neutralized 
in FO ACM. Overall, our data suggests that Ad and LC n-3 
PUFA work together to affect the macrophage phenotype in a 
microenvironment representative of obese AT. Additionally, this 
relationship warrants further study in vivo to further understand 
the role of dietary LC n-3 PUFA in mitigating obese AT inflam-
mation and related pathologies.
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